Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 17, 2024 - Issue 5-6
Submit an article Journal homepage
557
Views
0
CrossRef citations to date
0
Altmetric
Editorial

The thiazide-like diuretic chlorthalidone as an alternative evidence-based therapy for resistant hypertension in patients with stage 4 chronic kidney disease

Panagiotis I. Georgianosa 2nd Department of Nephrology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceCorrespondence[email protected]
View further author information
,
Vasilios Vaiosa 2nd Department of Nephrology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceView further author information
,
Ioannis Kontogiorgosa 2nd Department of Nephrology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceView further author information
,
Maria Divanib Hemodialysis Unit, General Hospital of Larissa, Larissa, GreeceView further author information
&
Vassilios Liakopoulosa 2nd Department of Nephrology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceView further author information
Pages 415-418 | Received 11 Jan 2024, Accepted 19 Mar 2024, Published online: 22 Mar 2024

References

  • Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American heart association. Hypertension. 2018;72(5):e53–e90. doi: 10.1161/HYP.0000000000000084
  • Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98–105. doi: 10.1136/heartjnl-2018-313599
  • Georgianos PI, Agarwal R. Resistant hypertension in chronic kidney disease (CKD): prevalence, treatment particularities, and research agenda. Curr Hypertens Rep. 2020;22(10):84. doi: 10.1007/s11906-020-01081-x
  • Thomas G, Xie D, Chen HY, et al. Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the chronic renal insufficiency cohort study. Hypertension. 2016;67(2):387–396. doi: 10.1161/HYPERTENSIONAHA.115.06487
  • Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA. 2003;289(19):2560–2572. doi: 10.1001/jama.289.19.2560
  • Mancia G, Kreutz R, Brunstrom M, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of hypertension: endorsed by the International Society of hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874–2071. doi: 10.1097/HJH.0000000000003480
  • Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2017;71(6):e13–e115. 2018. doi: 10.1161/HYP.0000000000000065
  • Williams B, Mancia G, Spiering W, et al. ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of hypertension. J Hypertens. 2018;36:1953–2041.
  • Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16(11):925–930. doi: 10.1016/S0895-7061(03)01032-X
  • Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–2068. doi: 10.1016/S0140-6736(15)00257-3
  • Trevisan M, de Deco P, Xu H, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018;20(8):1217–1226. doi: 10.1002/ejhf.1199
  • Leon SJ, Whitlock R, Rigatto C, et al. Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: A population-based cohort study. Am J Kidney Dis. 2022;80(2):164–173. doi: 10.1053/j.ajkd.2022.01.002
  • Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10208):1540–1550. doi: 10.1016/S0140-6736(19)32135-X
  • Bakris G, Pergola PE, Delgado B, et al. Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study. Hypertension. 2021;78(1):74–81. doi: 10.1161/HYPERTENSIONAHA.121.17073
  • Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021;385:2507–2519.
  • Agarwal R, Cramer AE, Balmes-Fenwick M, et al. Design and baseline characteristics of the chlorthalidone in chronic kidney disease (CLICK) trial. Am J Nephrol. 2020;51(7):542–552. doi: 10.1159/000508700
  • Agarwal R, Sinha AD, Tu W. Chlorthalidone for resistant hypertension in advanced chronic kidney disease. Circulation. 2022;146:718–720.
  • Agarwal R. Spironolactone and chlorthalidone—old drugs, new uses—but approach with caution. Nephrol Dial Transplant. 2022;37(3):407–408. doi: 10.1093/ndt/gfab328

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.